The Evaluation of Coffee Therapy for Improvement of Renal Oxygenation (COFFEE) Study: A Mechanistic Pilot and Feasibility Study Evaluating Coffee’s Effects on Intrarenal Hemodynamic Function and Renal Energetics

Kalie L. Tommerdahl1,2,3, Carissa Vinovskis1, Lu-Ping Li4,5, Casey M. Rebholz6,7,8, Cameron Severn1,9, Emily A. Hu6,7, Elizabeth Selvin6,7, Josef Coresh6,7, Morgan E. Grams6,8, Pottumarthi Prasad4,5, Chirag R. Parikh8 and Petter Bjornstad1,3,10

1Department of Pediatrics, Section of Pediatric Endocrinology, Children’s Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; 2Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA; 3Ludeman Family Center for Women’s Health Research, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; 4Department of Radiology, NorthShore University HealthSystem, Evanston, Illinois, USA; 5Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA; 6Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland, USA; 7Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; 8Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; 9Department of Biostatistics, Colorado School of Public Health, Aurora, Colorado, USA; and 10Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

Correspondence: Petter Bjornstad, Section of Pediatric Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, 13123 East 16th Avenue, Box B265, Aurora, Colorado 80045, USA. E-mail: Petter.Bjornstad@childrenscolorado.org

Received 19 February 2022; revised 14 April 2022; accepted 25 April 2022; published online 4 May 2022

Kidney Int Rep (2022) 7, 1682–1685; https://doi.org/10.1016/j.ekir.2022.04.096

KEYWORDS: beverages; caffeine; coffee; intraglomerular hemodynamic function; renal energetics

© 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

Coffee remains one of the most widely consumed beverages in the United States with an estimated 400 million cups ingested daily.1 Extensive studies have revealed a wide variety of health benefits attributed to coffee consumption, and in a meta-analysis of 3 large prospective studies involving 208,501 adults, consumption of both caffeinated and decaffeinated coffee was associated with a lower risk of all-cause mortality.2 One potential explanation for the survival benefit of coffee consumption is protection against kidney disease. Indeed, habitual coffee consumption was associated with a lower incidence of chronic kidney disease (CKD) in the Atherosclerosis in Communities study, a large population-based study of 14,209 older adults.3 Yet, the specific physiological effects of coffee on kidney function that may contribute to improvements in morbidity and mortality have not yet been elucidated.

Regular coffee contains multiple potential kidney-modifying compounds, including caffeine, a methylxanthine alkaloid which acts as an antagonist of the adenosine receptor,4 and polyphenol bioactive compounds, which serve as plant-based antioxidants.5 Caffeine has been found to modify kidney hemodynamics and natriuresis through factors including inhibition of proximal and distal tubule sodium reabsorption to promote free water and solute excretion and modification of the renin-angiotensin-aldosterone system.4,6 In response to sodium delivery to the distal tubule, caffeine has also been hypothesized to inhibit the tubuloglomerular feedback response and may maintain glomerular filtration rate (GFR) and renal plasma flow (RPF) while concurrently reducing consumption of renal oxygen (O2). In conjunction with the beneficial effects of caffeine, bioactive compounds in coffee have also been found to improve oxidative stress and inflammation, known contributing factors for kidney injury.5,7 However, to date, there are no data
evaluating the influence of coffee-induced and/or caffeine-induced natriuresis on intrarenal hemodynamic function and renal energetics in youth-onset type 1 diabetes (T1D), a population at high risk for CKD. Youth with T1D were selected for this study as we have previously found that adolescents with T1D exhibit relative renal hypoxia when compared with healthy controls and this is associated with increased RPF, albuminuria, and insulin resistance,8 thus making youth with T1D an ideal focus for therapeutic strategies targeting intraglomerular hemodynamic dysfunction and renal hypoxia as precursors for future DKD.

In the Evaluation of Coffee Therapy for Improvement of Renal Oxygenation (COFFEE) Study (NCT03878277), a study of 10 youths aged 12 to 21 years with T1D, we aimed to assess the effects of a 7-day course of a single daily Starbucks Cold Brew (325 ml, 175 mg caffeine) coffee on intraglomerular hemodynamic function by RPF and GFR and renal oxygenation by kidney functional magnetic resonance imaging (Supplementary MethodsS1–S3). We hypothesized in this open-label, pilot, and feasibility trial that daily coffee consumption would improve renal oxygenation without changes in GFR and RPF.

### RESULTS

#### Baseline Characteristics

COFFEE participants had a mean age ± SD of 18.5 ± 2.6 years with a T1D duration of 5.9 ± 2.2 years and a mean hemoglobin A1c of 8.4 ± 1.0% (Table 1). The participants were predominantly male (60%), and all identified as White/non-Hispanic.

### Table 1. Characteristics of participants in the COFFEE study at baseline

| Characteristics         | Baseline value |
|-------------------------|----------------|
| Age (yr)                | 18.5 ± 2.6     |
| Type 1 diabetes duration (yr) | 5.9 ± 2.2     |
| Sex (female, %)         | 40             |
| Race/ethnicity (%)      |                |
| Black non-Hispanic      | 0              |
| Hispanic                | 0              |
| White non-Hispanic      | 100            |
| Fat mass (kg)           | 16.6 ± 7.0     |
| Hemoglobin A1c (%)      | 8.4 ± 1.0      |

Caffeinated compound intake (units per wk)

|                    | Pre-therapy | Post-therapy | P value |
|--------------------|-------------|--------------|---------|
| Regular coffee (6 oz) | 2 (0–10)  |              |         |
| Espresso beverage  | 0 (0–0)     |              |         |
| Caffeinated soft drink (12 oz) | 2 (0–3.5) |                |         |
| Block or green tea (6 oz) | 0 (0–0)   |              |         |
| Energy drink (12 oz) | 0 (0–2)    |              |         |
| Chocolate bar (8 oz) | 2 (0–2)    |              |         |
| Aspirin/paracetamol/caffeine (Excedrin) | 0 (0–0) |                |         |

Data are presented as mean ± SD or median (interquartile range) unless otherwise noted.

### Table 2. Characteristics of participants in the COFFEE study pre-coffee and post-coffee therapy

| Characteristics          | Pretherapy (n = 10) | Post-therapy (n = 10) | P value |
|--------------------------|---------------------|-----------------------|---------|
| BMI (kg/m²)              | 22.5 ± 4.1          | 23.0 ± 4.3            | 0.77    |
| Weight (kg)              | 67.4 ± 14.4         | 68.4 ± 14.2           | 0.08    |
| SBP (mm Hg)              | 116 ± 5             | 121 ± 11              | 0.25    |
| DBP (mm Hg)              | 77 ± 10             | 73 ± 14               | 0.19    |
| Serum creatinine (µmol/l) | 70.7 ± 21.2       | 70.7 ± 19.5           | 0.68    |
| Cystatin C (mg/l)        | 0.82 ± 0.18         | 0.84 ± 0.19           | 0.92    |
| Hematocrit (%)           | 43.3 ± 2.8          | 42.4 ± 2.5            | 0.48    |
| UACR (mg/mmol)           | 0.45 (0.34–0.68)    | 0.45 (0.45–0.68)      | 0.37    |
| GFR (ml/min)             | 195 ± 28            | 196 ± 48              | 0.97    |
| RPF (ml/min)             | 785 ± 95            | 781 ± 40              | 0.69    |
| Cortex R2* (s⁻¹)         | 20.2 ± 1.4          | 20.0 ± 1.9            | 0.59    |
| Medulla R2* (s⁻¹)        | 27.1 ± 3.2          | 27.1 ± 3.4            | 0.98    |
| Whole kidney R2* (s⁻¹)   | 22.4 ± 1.5          | 22.5 ± 2.1            | 0.93    |
| FSOC (cortex) (s⁻¹)      | 1.41 ± 0.78         | 0.69 ± 0.65           | 0.11    |
| FSOC (medulla) (s⁻¹)     | 6.30 ± 2.19         | 5.68 ± 2.76           | 0.67    |
| FSOC (whole kidney) (s⁻¹) | 3.04 ± 0.97     | 2.67 ± 1.46           | 0.61    |
| Renal blood flow by 3D pCASL (right) (ml/100 g/min) | 181 ± 40 | 182 ± 37 | 0.97 |
| Renal blood flow by 3D pCASL (left) (ml/100 g/min) | 189 ± 30 | 182 ± 43 | 0.14 |

BMI, body mass index; DBP, diastolic blood pressure; 3D pCASL, 3-dimensional pseudocontinuous arterial spin labeling; FSOC, furosemide-suppressible oxygen consumption = R2* (baseline) − R2* (post-furosemide); GFR, glomerular filtration rate; R2*, the transverse magnetization decay time proportional to the tissue content of deoxyhemoglobin; RPF, renal plasma flow; SBP, systolic blood pressure; UACR, urinary albumin-to-creatinine ratio. Data are presented as mean ± SD or median (interquartile range) unless otherwise noted.

### Pre-Coffee and Post-Coffee Outcomes

Participant weight, systolic blood pressure, and diastolic blood pressure did not differ significantly after a 1-week course of coffee consumption (Table 2). Serum creatinine, cystatin C, hematocrit, and urine albumin-to-creatinine ratio also remained similar across the 2 time points. Gold standard measures of GFR by ioxelox clearance and of RPF by p-aminohippurate clearance did not differ significantly before and after coffee consumption. Kidney blood oxygen level-dependent magnetic resonance imaging revealed no significant changes between the baseline and follow-up visits for the cortex, medulla, or whole kidney R2* (fractional oxygenation), furosemide-suppressible oxygen consumption, or 3-dimensional pseudocontinuous arterial spin labeling on the right or left (perfusion).

### DISCUSSION

Coffee consumption is highly prevalent in both youth and young adults, yet our knowledge of its underlying physiological effects remains limited. In the Atherosclerosis in Communities study, attenuation of CKD risk was found in adults without diabetes who consumed higher amounts of coffee daily,3 and we hypothesized that this may be secondary to coffee-induced
improvements in kidney oxygenation with maintenance of GFR and RPF. Yet, in an exploratory analysis from the COFFEE pilot and feasibility study, consumption of a single, daily, cold-brew coffee in a small group of young persons with T1D with habitual caffeine intake did not significantly affect intraglomerular hemodynamic function or kidney oxygen availability.

To best of our knowledge, ours is the first study to evaluate the impact of coffee consumption on intraglomerular hemodynamic function and kidney energetics in T1D. From the results of this pilot study, we may conclude that either our small sample size has diminished our power too considerably to see a potential significant difference over time or the mechanisms whereby coffee mediates the cardiorenal protective effects observed in epidemiologic studies may be independent of the effects of coffee on intraglomerular hemodynamics and kidney energetics. Additional predisposing factors for the development of kidney injury, such as elevated age, acute illness, or baseline CKD, which were absent in our current cohort, may be also necessary to fully identify the kidney protective effects of coffee.

Strengths of COFFEE include its prospective interventional study design and the collection of gold standard measures of GFR and RPF by iohexol and p-aminohippurate clearance techniques, while maintaining steady-state glycemic concentrations to avoid glycemic variability and mimic the typical hyperglycemic milieu of T1D. COFFEE used state-of-the-art multiparametric kidney magnetic resonance imaging assessments for kidney oxygenation and perfusion as well. Notably, measurements of kidney oxygenation and perfusion by blood oxygen level-dependent magnetic resonance imaging and pseudocontinuous arterial spin labeling have been effectively used in populations with and without diabetes or with varying degrees of CKD and have consistently revealed associations between low oxygenation and kidney function decline.9

Limitations of COFFEE include the small sample size, as it was designed as a pilot, and the homogeneous non-Hispanic White race/ethnicity (a common finding in T1D studies in Colorado, USA) and younger age demographic, with less potential for age-related kidney dysfunction. Accordingly, further research is necessary before rejecting modification of renal bioenergetics and hemodynamics as potential protective mechanisms of coffee consumption. It is notable that individuals in the COFFEE study had a baseline diagnosis of T1D, which places them at higher risk for kidney injury than their peers without diabetes because of factors including chronic poor glycemic control, acute hyperglycemic events, dehydration, and potential diabetic ketoacidosis,S24 and therefore have greater potential for improvement in response to coffee consumption.

In conclusion, although we did not identify significant changes over time in GFR, RPF, or renal perfusion or oxygenation in response to a short treatment course of daily coffee in this small pilot and feasibility study involving youth with T1D, further large-scale studies in youth and adults with and without diabetes are necessary to better understand and optimize the long-term beneficial effects of habitual coffee consumption on cardiorenal protection.

DISCLOSURE
PB has reported acting as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, LG Chem, Sanofi, Novo Nordisk, and Horizon Pharma and serving on the advisory boards of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and XORTX. CRP has reported serving as a member of the advisory board of and owning equity in RenalytixAI and as a consultant for Genfit and Novartis. All the authors declared no competing interests.

ACKNOWLEDGMENTS
The authors thank the staff and participants of the CASPER and COFFEE studies for their important contributions. KLT receives salary and research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (K23 HL159292), Children’s Hospital Colorado Research Institute Research Scholar Award, University of Colorado Diabetes Research Center (P30 DK116073), Ludeman Family Center for Women’s Health Research at the University of Colorado, ISPAD-JDRF Research Fellowship, and the Department of Pediatrics, Section of Endocrinology at the University of Colorado School of Medicine. LPL and PP are supported in part from the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (R21 DK127302), CMR was supported by grants from the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (K01 DK107782, R03 DK128386) and the NIH/NHLBI (R01 HL153178). ES was supported by the NIH/NHLBI (K24 HL152440). PB receives salary and research support from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK129211, R21 DK129720, K23 DK116720, UC DK114886, and P30 DK116073), JDRF (2-SRA-2019-845-S-B, 3-SRA-2017-424-M-B), Boettcher Foundation, American Heart Association (20IPA35260142), Ludeman Family Center for Women’s Health Research at the University of Colorado, the Department of Pediatrics, Section of Endocrinology and Barbara Davis Center for Diabetes at University of Colorado School of Medicine. CRP is supported by NIH/
NHLBI (R01 HL085757) and NIH/National Institute of Diabetes and Digestive and Kidney Diseases (UH3 DK114866, U01 DK106962, R01 DK093770). The funders had no role in the study design; collection, analysis, and interpretation of the data; and writing the report; or the decision to submit the report. The interpretation and reporting of the data are the responsibility of the authors and in no way should be seen as official policy or interpretation of the US government. This study was funded by ClinicalTrials.gov identifiers: NCT03618420 (CASPER) and NCT03878277 (COFFEE).

AUTHOR CONTRIBUTIONS
KLT analyzed and interpreted the data and wrote the manuscript. CV collected, analyzed, and interpreted the data. LPL assisted with MRI postprocessing and analyses. CMR, CS, EAH, ES, LMS, JC, and MEG analyzed and interpreted the data. PP developed the magnetic resonance imaging protocols, postprocessing, and analyses. CRP designed the study, analyzed and interpreted the data, and contributed to discussion. PB designed the study, collected the data, analyzed and interpreted the data, and contributed to discussion. All coauthors reviewed and edited the manuscript. PB is the guarantor of this work and, as such, has full access to the data sets and takes responsibility for the integrity of the data and the accuracy of the data analysis.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Supplementary Methods.
Supplementary References.

REFERENCES
1. Patil H, Lavie CJ, O’Keefe JH. Cuppa joe: friend or foe? Effects of chronic coffee consumption on cardiovascular and brain health. Mo Med. 2011;108:431–438.
2. Ding M, Satija A, Bhupathiraju SN, et al. Association of coffee consumption with total and cause-specific mortality in 3 large prospective cohorts. Circulation. 2015;132:2305–2315. https://doi.org/10.1161/CIRCULATIONAHA.115.017341
3. Hu EA, Selvin E, Grams ME, Steffen LM, Coresh J, Rebholz CM. Coffee consumption and incident kidney disease: results from the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis. 2018;72:214–222. https://doi.org/10.1053/j.ajkd.2018.01.030
4. Brown NJ, Ryder D, Nadeau J. Caffeine attenuates the renal vascular response to angiotensin II infusion. Hypertension. 1993;22:847–852. https://doi.org/10.1161/01.hyp.22.6.847
5. Iglesias-Aguirre CE, Cortes-Martin A, Avila-Galvez MA, et al. Main drivers of (poly)phenol effects on human health: metabolite production and/or gut microbiota-associated metabotypes? Food Funct. 2021;12:10324–10355. https://doi.org/10.1039/d1fo02033a
6. Passmore AP, Kondowe GB, Johnston GD. Renal and cardiovascular effects of caffeine: a dose–response study. Clin Sci (Lond). 1987;72:749–756. https://doi.org/10.1042/cs0720749
7. Sureshbabu A, Ryter SW, Choi ME. Oxidative stress and autophagy: crucial modulators of kidney injury. Redox Biol. 2015;4:208–214. https://doi.org/10.1016/j.redox.2015.01.001
8. Vinovskis C, Li LP, Prasad P, et al. Relative hypoxia and early diabetic kidney disease in type 1 diabetes. Diabetes. 2020;69:2700–2708. https://doi.org/10.2337/db20-0457
9. Pruijm M, Milani B, Pivin E, et al. Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int. 2018;93:932–940. https://doi.org/10.1016/j.kint.2017.10.020